ehealth radio network
Episodes
Monday Mar 07, 2016
Monday Mar 07, 2016
Dr. Alan Jacobs M.D., Ph.D., Founder and President of PerceptiMed that was founded in 2011 with a driving purpose — to reduce the margin of human error in prescription pill dispensing in retail pharmacies, long-term care facilities and hospitals joins eHealth Radio and the Health News and Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Dr. Alan Jacobs discuss the following: Can you explain the situation involving your father-in-law that led you to start PerceptiMed?What feelings ran through your head when you discovered that a medication error threatened a loved one’s life?As a physician, were you surprised to uncover the prevalence of medication errors?What is the mission of PerceptiMed?Can you give us a background on IdentRx and the impact you see it making on the healthcare industry?How does the Ident-Rx remote allow PerceptiMed to service patients in rural areas?How can MedPass be a valuable asset to hospitals and long-term care facilities? What is ScripClip and how can ScripClip be a valuable technology for pharmacies?If you could give any advice to people for them to self-identify medications, what would that be?
Duration: 16:40
Alan Jacobs, M.D., Ph.D., the President, CTO & Founder of PerceptiMed is driven to reduce the margin of human error in the administration of prescription drugs. As such, he has focused on creating “first-in-class” technology that eliminates medication errors in retail pharmacies, long-term care facilities and hospitals.
He holds several key patents and is the co-inventor of the IdentRx™ medication verification system. Alan has extensive experience leading international teams in the research and development of therapeutics and medical devices. He began his research and development career at Elan Pharmaceuticals where he designed and managed clinical drug trials, drug development protocols and safety infrastructures for investigating treatments of traumatic brain injury and peri-operative pain management. Dr. Jacobs has also led the clinical development of novel therapeutics at Layton BioScience and Titan Pharmaceuticals before serving as CMO and Vice President of Clinical Research at Stem Cells, Inc., where he led the clinical team developing novel treatments for Batten’s disease.
Alan received a B.S.E.E. from Cornell University and a M.S.E.E from Stanford University. He also holds a Medical Doctorate from the School of Medicine at University of Pennsylvania and a Ph.D. from the David Mahoney Institute of Neuroscience, University Pennsylvania, where he was a Fellow, in the Medical Scientist Training Program of the National Institute of General Medical Sciences. Alan completed an internship in General Surgery and was a resident in Neurological Surgery at the University of California, San Francisco Medical Center.
Website: www.perceptimed.com
Social Media Links:
Facebook: Facebook-PerceptiMed
Linkedin: https://www.linkedin.com/company/perceptimed
Twitter: @perceptimed
Wednesday Feb 10, 2016
Wednesday Feb 10, 2016
Armando Bardisa, President & Founder of SMP Pharmacy Solutions, a specialty pharmacy that is redefining the pharmacy experience through its comprehensive approach to healthcare and its commitment to providing superior customer service and improved patient health joins eHealth Radio and the Health News, Health Care & Pharmaceutical Channels.
Listen to interview with host Eric Michaels & guest Armando Bardisa discuss the following: How did you get into the healthcare industry?Did being a pharmacist by trade have any advantages while you were starting up your business?How does SMP compete with the big box pharmacies like Walgreens and CVS?What does it mean to be a specialty pharmacy?What advice do you have for young entrepreneurs who are looking to get into the healthcare industry today?
Duration: 7:31
Armando Bardisa, Pharm.D, C.Ph., is the President & Founder of SMP Pharmacy Solutions. Dr. Armando Bardisa founded South Miami Pharmacy in 2003 in an effort to improve the quality of life for patients through personalized pharmacy service. A pharmacist by trade and an entrepreneur at heart, Armando has led the company to many notable achievements including the prestigious honor of being named one of the 5000 Fastest Growing Private Companies by Inc. Magazine for seven consecutive years. In addition, SMP was recognized by J.D. Power & Associates as having the “Highest in Customer Satisfaction” rating and was also named a Top 500 Hispanic-Owned Business by Hispanic Business Magazine. Drug Topics Magazine named SMP an “Independent Pharmacy Superstar,” and the company was also recognized by Drug Channels as one of the top ten fastest-growing, private specialty pharmacies. In 2015, South Miami Pharmacy changed its name to SMP Pharmacy Solutions to redefine the company’s position as one of the top independent pharmacies in the country and a trusted healthcare partner to both patients and physicians alike.
Armando is the driving force behind SMP’s four points of service that include compounding, fertility, specialty and retail. He is certified by the American Academy of Anti-Aging Medicine (A4M), a prestigious medical organization that grants physicians and pharmacists the ability to detect, treat and prevent diseases related to the human aging process. SMP Compounding is accredited by the Pharmacy Compounding Accreditation Board (PCAB) and the Professional Compounding Center of America (PCCA), of which Armando is also a member. In addition, SMP has become a national leader in mail order fertility and specialty services, and has a presence in over 31 states.
Committed to playing a role in the future of the pharmaceutical industry, Armando lends his expertise to numerous boards including Nova Southeastern University’s College of Pharmacy Dean’s Advisory Board. He is also on the Board of Directors for the Pharmacy Development Services (PDS), an organization that coaches and trains independent pharmacy owners with the skills they need to be successful. Armando is a member of several industry-centric groups including the American Association of Colleges of Pharmacy, American Pharmacists Association and Specialty Pharmacy Association of America (SPAARx).
Armando compliments his business success with various philanthropic partnerships including the support of Susan G. Komen foundation and St. Jude Children’s Research Hospital, where he participates in the annual triathlon, raising over $50,000 in donations to date. SMP has also provided medicine and medical supplies for various medical missions in Guatemala, Haiti and Honduras. Locally, Armando supports the annual Migrant Toy Drive in Homestead and Blossom’s Developmental Therapy Associates (BDTA), a state-of-the-art facility that provides service and programs for children with special needs, specifically cerebral palsy. This year Armando will participate in the New York City Marathon, running to raise money for Team for Kids, an organization that provides low-cost health and fitness programs to kids who have little access to regular physical activity.
Armando received his Doctor of Pharmacy from Nova Southeastern University, a Bachelor of Science degree from Florida International University and his Consultant Pharmacist License from the University of Florida. In 2010, Armando was awarded an honorary MBA from Florida International University for his success in the pharmaceutical industry. In addition, Armando has been a notable speaker at Pharmacy Development Services’ Showcase of Success, as well as a contributing writer to many local Miami and industry publications including Drug Topics magazine and South Florida Business Journal.
Website: www.smppharmacy.com
Social Media Links:Facebook: https://www.facebook.com/SouthMiamiPharmacy
Twitter: @smiamipharmacy
Wednesday Jan 20, 2016
Wednesday Jan 20, 2016
Jeff Abraham, CEO of Promescent, the first FDA-compliant topical treatment spray for PE joins eHealth Radio and the Men's Health, Pharmaceutical & Sexual Health Channels. Promescent is one of the few sexual products on the market that is backed by more than 1,000 urologists nationwide.
Listen to interview with host Eric Michaels & guest Jeff Abraham discuss the following: Promescent is now considered the leading PE solution in the U.S, is heavily supported by the medical community, and is believed to safely and effectively improve men's sex lives. How does Promescent work and how is it able to help the population of over 30% of males who currently suffer from PE, or simply those who want to last longer in bed?How does the effectiveness and convenience factor of Promescent compare to competitors and other ED sprays/creams on the market? What makes it so different and why do over 1,000 urologists in the US consider it to be first-line therapy for premature ejaculation? One of the major agreements between men and women, according to research, on what makes sex great is whether or not there was an orgasm. Could you explain the orgasm gap and dispel any myths surrounding how long should great sex actually last?The product has recently been dubbed "The Next Viagra" and while the sales figures of Promescent are a far cry from Viagra, there is significant potential in the market for this product since ED is talked about more by PE affects more men. As the leader of this company, what is your vision for Promescent over the next few years and how to do your hope to achieve it? It's New Year's resolution season, and lots of couples have certain "sexpectations" for 2016. What are some of your favorite resolution ideas for better, healthier sex this year- whether it be for marriages, singles, "it's complicated" relationships, etc.? And where can these couples purchase Promescent?
Duration: 17:26
Jeff Abraham is the CEO of Absorption Pharmaceuticals, responsible for the company's strategic direction and operations. With his entrepreneurial spirit, Jeff created Absorption Pharmaceuticals in 2011 and introduced Promescent®, an FDA-approved, lidocaine-based topical premature ejaculation (PE) prevention topical spray conceived by the late Dr. Ronald Gilbert at the American Urological Association (A.U.A) conference in Washington, D.C.
Recently, Jeff has also become involved in angel investing and managing a number of innovative companies, including those specializing in diabetes care, contract manufacturing and crop yield utilization.
Prior to launching Promescent, Jeff founded Technical Resources in 1988, a semiconductor technology search firm to better suit the staffing needs of the industry. His one man company grew to nine full-time recruiters/researchers, and 200 engineers working at various fabrication plants, within 10 years.
With all his success, Jeff is passionate about giving back and is an active member of the Big Brothers organization, as well as a member and regular contributor to the local Center for Social Resources to help the underprivileged in Orange County, CA.
Jeff is a graduate of Edinboro University in Pennsylvania.
Websites: www.promescent.com
Social Media Links:
Facebook: https://www.facebook.com/Promescent
Twitter: https://twitter.com/Promescent
Instagram: https://www.instagram.com/promescent
Wednesday Aug 05, 2015
Wednesday Aug 05, 2015
Josh Hexter, Chief Operating Officer of Oramed Pharmaceuticals, a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems including what would be the first oral formulation of insulin joins eHealth Radio and the Diabetes, Pharmaceutical, & Health News Channels.
Listen to interview with host Eric Michaels and guest Josh Hexter discuss the following:Many listeners may be familiar with diabetes, either they are affected or know a family member affected by the condition. Can you explain to our listeners the differences between the Type I and II diabetes? What toll does this disease create?What role does insulin play in diabetes? Why has it taken so long for researchers to turn insulin into a pill? What has been the challenges? Your company is working on an oral version of insulin. Can you describe how does it work and what stage are you in drug’s development? Can you explain why treating patients who may be at risk for Type II diabetes (prediabetes) with Oramed’s oral pill? What protection does the oral version of insulin provide?
Duration: 14:35
Mr. Hexter serves as Chief Operating Officer and Vice President of Business Development of Oramed Pharmaceuticals, which he joined in 2013. He brings to Oramed more than 15 years of prominent leadership, business development, operations know-how and management in the life science sector. He was most recently Executive Director of Corporate In-Licensing at BioLineRx Prior to joining BioLineRx, he worked in private equity and venture capital where he served as CEO of a VC-backed startup.
As CEO of Biosensor Systems Design, Mr. Hexter was instrumental in shaping the company’s strategic focus and in forging business development agreements with Fortune 100 companies in the areas of food safety, medical diagnostics and homeland security. Mr. Hexter earned a bachelor’s degree from the University of Wisconsin and a master’s degree in management from Boston University.
Website: www.oramed.com
Tuesday Jun 02, 2015
Tuesday Jun 02, 2015
Dan Edwall, Vice President of Research and Development at Greenleaf Medical, a Swedish research and development company that develops and sells natural ingredients with well-documented health benefits on the global nutraceutical market, including Appethyl joins eHealth Radio and the Nutrition, Pharmaceutical & News Channels.
Listen to interview with host Eric Michaels & guest Dan Edwall discuss the following:What are thylakoids?How do thylakoids work to control appetite?What other benefits do thylakoids have?How does ingesting thylakoids differ from eating regular spinach?What are ways that people can consume them?Tell me about Appethyl.
Duration: 9:58
Dan Edwall is the Vice President of Research and Development at Greenleaf Medical, a Swedish research and development company that develops and sells natural ingredients with well-documented health benefits on the global nutraceutical market, including Appethyl.
Appethyl is an all-natural, patented spinach extract that slows down the absorption of fat and glucose into the body, making the user feel fuller, faster. Made from 100% spinach, Appethyl is carefully processed in a proprietary and patented method in order to free the active substances–thylakoids–that are inside the spinach cells, making them active the moment the supplement is ingested.
Website: www.appethyl.com
Friday May 29, 2015
Friday May 29, 2015
Dr. Mona Vand, The Modern Pharmacist who is also a health and wellness expert joins eHealth Radio and the Pharmaceutical, Health Care & News Channels.
Listen to interview with host Eric Michaels & guest Dr. Mona Vand discuss the following:Tell our listeners What are compounding pharmacies?Why is compounding not utilized more? Can compounding benefit children, and if so, how?What supplements do you recommend the most to patients at the pharmacy?When a medication is not covered by a patient's insurance, what other (or affordable) options do they have?
Duration: 6:50
Growing up in a bi-coastal family, Dr. Mona Vand‘s parents could see from an early age that she had a deep passion for science and helping people – something she’s now taking to an exciting global level with the launch of her multi-faceted health and wellness
website and web series, centered around her passion as The Modern Pharmacist.
Dr. Mona Vand attended the prestigious Massachusetts College of Pharmacy and Health Sciences.
“Pharmaceutical science approaches health from so many different angles. I knew almost immediately that I could accomplish the goals I am passionate about with a pharmacy degree. Having the ability to work with people, understand how chemicals work in the body, and one day work to develop my own health and wellness products was something I strived for,” says Dr. Mona. “Once I was in school, I loved learning the science of different medicines, how they work and how the body reacts to them. I also became excited about nutrition, which is a very large aspect of overall wellness. I always wondered if there would be a way to combine everything I was interested in and share it with people in a meaningful way. There’s a natural connection between pharmaceuticals and overall wellness, and I’m really excited to start connecting the two.”
Now, as The Modern Pharmacist, the beautiful and charismatic media entrepreneur is doing just that, combining her extensive expertise in pharmacy with her deep interest and expertise in nutrition, beauty, fitness and overall wellness. In addition to putting a fresh new face on the traditional world of pharmacy, Dr. Mona’s soon-to-launch website – and the ambitious slate of multi-media platforms to follow – uniquely positions her as the Dr. Oz and Rachel Ray of The Modern Pharmacist movement, whose mission is to help patients understand the connection between pharmaceutical science and overall wellness.
Conceived by and featuring all exclusive content by Dr. Mona, The Modern Pharmacist website – which has earned the sponsorship of Opus Rx, one of the country’s largest compounding pharmacy organizations – showcases her as the “go to” person for all types of health and wellness questions.
While Dr. Mona’s intense six years of pharmacy school and many years of professional experience as a Compounding Pharmacist in Los Angeles leaves her with a wealth of information to share, she points out that she’s also just a normal woman who wants to help people in a relatable way. “I’m a professional who is excited about sharing my knowledge with the world,” she says.
“People with important questions about medicine and other wellness topics don’t always have access to someone with my kind of diverse expertise who can help them,” Dr. Mona adds. “Anyone who knows me is aware that I could talk forever about health, wellness and medication, and I have always found it rewarding to counsel people who need help or want a deeper knowledge of things to better take control of their
health.
Dr. Mona’s road to becoming The Modern Pharmacist has found her at a crossroads of tradition and ambition. After graduating as a Doctor of Pharmacy, she settled in L.A. and worked first as a retail pharmacist before switching to a clinical pharmacy where she specialized in compounding – a fast growing part of the field that allows pharmacists to create customized strengths, combine ingredients, compound a tablet or capsule into a liquid, eliminate preservatives and prepare special formulations.
“All of this is driven by my passion for so many things,” says Dr. Mona. “Just like someone who is into cars who wants to talk about them all day long, I love to talk about wellness and medicine – and I am lucky to have chosen a profession that allows me to do that. When you love something, you want to share it, just like when something exciting happens in your life and you want to post the moment on Facebook. I have so much information that I want people to know and I want to be that trusted resource they can turn to for answers, insights and compassion. It’s a proven fact that when people go to doctor’s offices, their blood pressure goes up because of anxiety, or what we in the industry call ‘white coat syndrome.’ I’ve been wearing the white pharmacist coat for a long time, but I’m here to put people at ease and show that there’s nothing to be nervous about. I’m here to help!”
Website: www.drmonavand.com
Monday May 04, 2015
Monday May 04, 2015
Mr. Jeffrey Davis, COO of PlasmaTech BioPharmaceuticals, a Dallas & New York-based biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care joins eHealth Radio and the Pharamceutical, Health Care & News Channels.
Listen to interview with host Eric Michaels & guest Mr. Jeffrey Davis discuss the following:What is Inherited COPD? Who does it affect?Why does the World Health Organization and the American Thoracic Society recommend that every individual diagnosed with COPD be tested for Alpha-1?How do these patients get the Alpha-1 Anti-trypsin that they need?Why could we see a shortage of this drug in a few years?How can your Company’s technology change that?What resources are available for those with Inherited COPD?
Duration: 8:10
About PlasmaTech Biopharmaceuticals, Inc.
PlasmaTech Biopharmaceuticals, Inc. (PlasmaTech) is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, Salt Diafiltration (SDF™) Process and Polymer Hydrogel Technology (PHT™), PlasmaTech is active in the development and commercialization of plasma-derived therapeutics and cancer supportive care products. The company has developed a robust product pipeline that includes two commercial stage products, MuGard® and ProctiGard™ as well as multiple pre-clinical follow-on products. For more information visit, www.plasmatechbio.com.
Jeffrey B. Davis holds a B.S. in biomedical engineering from Boston University and an MBA degree from the Wharton School, University of Pennsylvania. Mr. Davis has held a variety of c-level executive positions in the biotechnology industry, and is currently a Director and Chief Operating Officer of PlasmaTech Biopharmaceuticals, Inc.
Mr. Davis was previously CEO of Access Pharmaceuticals, Inc., and has previously served in a variety of senior investment banking and management positions. Mr. Davis was an investment banker with various Deutsche Bank AG banking organizations, both in the U.S. and Europe. Mr. Davis also served in senior marketing and product management positions at AT&T Bell Laboratories, where he was also a member of the technical staff, and at Philips Medical Systems North America.
Website: www.plasmatechbio.com
Monday Mar 02, 2015
Monday Mar 02, 2015
Libby Baney, Founder and Executive Director of the Alliance for Safe Online Pharmacies, an international non-profit organization dedicated to protecting consumers from illegal online drug sellers joins eHealth Radio and the Pharmaceutical & Health News Channels.
Listen to interview with host Eric Michaels & guest Libby Baney discuss the following:What is the Alliance for Safe Online Pharmacies?Who are ASOP Global’s members?How many illegal online drug sellers are there?What are the risks associated with purchasing a prescription medication from illegal online drug sellers?What are the warning signs consumers should look for? How can a consumer know if an online pharmacy is legitimate?
Duration: 7:08
Libby Baney is the Founder and Executive Director of the Alliance for Safe Online Pharmacies (ASOP Global), an international non-profit organization based in Washington, D.C. In this capacity, Libby leads ASOP operations, shapes public policy, and advocates for increased international attention to the issue of illegal online drug sellers. Libby began working on Internet pharmacy issues in 2009 when she helped to launch a loose coalition, which grew into ASOP Global.
A lawyer by training and health advocate by nature, Libby is a prolific speaker and writer, regularly engaging with diverse audiences on issues at the intersection of Internet technology and healthcare. She leads strategic workshops and speaks on these issues worldwide; writes policy documents; and interacts with international corporate leaders and policymakers.
Libby’s work spans multiple continents, which has been covered by local, national and international media outlets including The Wall Street Journal, The Washington Post, Politico, Roll Call, The Hill, The Los Angeles Times, USA Today, The Washington Times, The Indianapolis Star, Inside Health Policy, Pharmacy Today, ABC News, CNN, and C-SPAN.
In addition to her work for ASOP, Libby is a Senior Director at FaegreBD Consulting and Counsel with Faegre Baker Daniels LLP where she works on Internet policy, intellectual property rights, pharmacy, telemedicine/telehealth, and pharmaceutical supply chain matters.
Website: www.safeonlinerx.com
Saturday Oct 18, 2014
Saturday Oct 18, 2014
Peter Culpepper, COO and CFO of Provectus Biopharmaceuticals specializing in developing oncology and dermatology therapies joins eHealth Radio and the Pharmaceutical & Cancer Prevention Channels.
Originally used as a coal tar–derived wool dye and most commonly been used as a stain for detecting ocular conditions, PV-10 is a rose bengal formulation now in clinical trials against cancer. Now, over 230 cancer patients have been treated with PV-10, including 12 in a Phase 1 recurrent breast cancer study. The PV-10 trials are now entering Phase II and so far have shown favorable results and may prove to be an arsenal against breast cancer. Peter Culpepper is here to discuss this novel approach.
Listen to interview with host Eric Michaels and guest Peter Culpepper discuss the following:Please tell us more about rose bengal, what makes it a an effective cancer fighter?How does PV10 work against recurrent breast cancer? What has been the response so far? What other types of cancer does PV-10 treat? How long before PV10 will be available to patients both affected by breast and skin cancers? How can patients find more information about trials?
Duration: 15:42
About Provectus Biopharma
Provectus Biopharmaceuticals, Inc., specializes in developing oncology and dermatology therapies. PV-10, its novel investigational drug for cancer, is designed for injection into solid tumors (intralesional administration), thereby reducing potential for systemic side effects. Its oncology focus is on melanoma, breast cancer and cancers of the liver.
The Company has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications. PH-10, its topical investigational drug for dermatology, is undergoing clinical testing for psoriasis and atopic dermatitis. Provectus has completed phase 2 trials of PV-10 as a therapy for metastatic melanoma, and of PH-10 as a topical treatment for atopic dermatitis and psoriasis.
About Peter R. Culpepper, CPA, MBA - Chief Financial Officer, Chief Operating Officer
Pete Culpepper has spent 20 years in the financial field working for a wide range of companies and industries in the U.S. and abroad, especially high-growth startups. His experience with for-profit companies ranges from private start-ups to publicly traded, global conglomerates. He also has worked with large non-profits and a national CPA accounting firm. He led the national operating unit of a $1 billion publicly traded telecommunications company, as well as numerous operating units in Eastern Europe for a global telecommunications company. He handled the capital reporting process for a $5 billion global construction project and the formation of systems for a division that grew $150 million in revenue in two years.
Previous employers include Neptec, Inc., a privately held optical networking component manufacturer; Metromedia Companies; and PageNet, the largest wireless messaging company in the world.
Culpepper taught undergraduate and graduate business courses for the University of Phoenix Online.
He is licensed as a Certified Public Accountant in Maryland and Tennessee.
His professional affiliations include the American Institute of Certified Public Accountants, Financial Executives International and the Financial Executives Networking Group.
Culpepper holds a master's of business administration (MBA) in finance from the University of Maryland. He earned an AAS in Accounting from the Northern Virginia Community College - Annandale, Virginia. He earned a bachelor's degree in philosophy from the College of William and Mary.
Link:
www.pvct.com
Link for clinical trials of PV-10:
http://clinicaltrials.gov/ct2/results?term=Provectus
Wednesday Oct 08, 2014
Wednesday Oct 08, 2014
Dr. William A. Carter who is the Chairman and CEO of Hemispherx Biopharma, a pharmaceutical company that is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders which includes Ebola joins eHealth Radio and the Pharmaceutical & Health News Channels.
Listen to interview with host Eric Michaels and guest Dr. William A. Carter discuss the following: The first case of ebola reported in the United States has caused great concern across the country. What should every citizen know about this virus and how it is spread?We understand that the ebola virus has the tendency to mutate as it spreads. What does this mean for the drugs that are currently being used to treat the virus?Hemispherx recently announced that the company is involved in five research collaborations designed to develop therapeutic cocktails against Ebola that may potentially overcome the emergence of drug resistance due to Ebola virus mutation. Could you please give us more details?If it is found that the company’s platform drugs Alferon N and Ampligen are effective in ebola cocktail therapies under development, what is the next step?
Duration: 11:35
Dr. Carter was a leading innovator in the development of human interferon for a variety of treatment indications including various viral diseases and cancer. In this context, he received the first FDA approval to initiate clinical trials on a beta interferon product manufactured in the U.S. under his supervision. As the recipient of the first IND to evaluate interferon in the U.S., Dr. Carter led numerous studies resulting in interferon being one of the most widely prescribed therapies in the U.S. Worldwide, interferon is now approved for treatment in more than 50 serious and debilitating diseases. From 1985 to October 1988, Dr. Carter served as the Company's Chief Scientific Officer. He received his M.D. degree (with high honors) from Duke University and underwent his post-doctoral training at both the National Institutes of Health in Allergy and Infectious Disease as well as on the Osler Medical Services of Johns Hopkins University. Thereafter, he joined the Department of Medicine and Microbiology and worked closely with Dr. Daniel Nathans who received the Nobel Prize in Medicine for his pioneering work in understanding the genetic code. He thereafter became Professor of Medicine at the University of New York at Buffalo as well as Chairman of the Department of Microbiology. Following his Buffalo, NY experiences, he returned to Philadelphia, PA where he served as Director of Clinical Research for the Hahnemann Medical University's Institute for Cancer and Blood Diseases, as well as a visiting Professor of Medicine at Johns Hopkins School of Medicine. He was a distinguished recipient of the Research Career Award from the National Institutes of Health while serving on the faculty of Johns Hopkins Medical University. This Research Career Award allowed him to participate in a broad range of studies of the body’s natural antiviral control system and gain a better understanding of the body’s antiviral pathways. He is a Board certified physician, licensed to practice medicine (Internal Medicine is his specialty), and licensed in Pennsylvania, Maryland, New York, and North Carolina. He is a Fellow of the American College of Physicians, American Society for Clinical Investigation, and author of more than 250 scientific articles, including the editing of various textbooks on antiviral and immune therapy which are widely used in medical school education.
In addition to his peer reviewed articles on antiviral therapy in human immunology, he has edited several textbooks and one, entitled “Selective Inhibitor of Animal Viruses”, has gone through more than 10 printings and is widely circulated in medical school classes. He was Principal Investigator on numerous large National Institutes of Health Program Project Grants in the area of antiviral and immunotherapy, with annual budgets of several million dollars. Private investments in his science and research have exceeded $500 million. Conspicuous in his achievements have been case studies of first reports of complete responses in chronic viral hepatitis and multiple sclerosis. Dr. Carter initiated some of the first clinical studies in a number of diseases in which interferon is now the treatment of choice, including chronic viral hepatitis and multiple sclerosis. He is the inventor, or co-inventor, of several hundred patents on pharmaceutical products.
He is considered an expert in treatment of a variety of diseases including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and is a leading innovator in treatment of the enigmatic disease Chronic Fatigue Syndrome (CFS). At present, he is mounting a program with a partner biotech company in South Africa in which the effort is to cure HIV/AIDS by strategic use of alpha interferon and/or Ampligen®, an immunomodulatory product co-discovered while at Johns Hopkins University, to be added after partial removal of the AIDS virus by traditional HIV/AIDS cocktails. The purpose of this programs effort is to remove trace amounts of AIDS virus which still exists in so-called sanctuary areas of the body following effort of AIDS cocktails to remove residual virus by immuno scavenging, a unique approach embodied in alpha interferon and Ampligen®.
The recent successful experiments in a National Institutes of Health laboratory inhibiting the MERS virus were an intellectual product of Dr. William Carter and clinical colleagues at Hemispherx.
Dr. Carter, the co-inventor of Ampligen®, has served as the Hemispherx's Chief Scientific Officer since May 1989, the Chairman of the Company's Board of Directors since January 1992, the Company's Chief Executive Officer since July 1993, the Company's President since April 1995, and a Director since 1987.
Website: www.hemispherx.net